Synthego, the genomic engineering company, today announced the launch of Eclipse ™, a new high-throughput cellular engineering platform designed to accelerate drug discovery and validation by delivering highly predictable CRISPR-engineered cells on a large scale through the integration of engineering , Bioinformatics and proprietary cells are provided science. The introduction of this unique CRISPR-based platform drives the company’s growing influence on research and development in the field of biopharmaceuticals and strengthens Synthego’s position as a leading provider of genomic engineering.
CRISPR engineered cells have a wide range of research and development applications in a variety of disease areas, including neuroscience and oncology. Synthego developed the Eclipse platform to improve disease modeling, drug target identification and validation, and accelerate the manufacture of cell therapies.
“With the industrialization of cell technology, Synthego’s Eclipse platform will enable economies of scale and transform a historically complex process into a flexible, reliable and affordable process,” said Dr. Bill Skarnes, Professor and Director of Cellular Engineering at The Jackson Laboratory and Synthego Advisory Board member: “Offering large-scale CRISPR changes, much like Synthego did with sgRNA reagents, enables researchers to do thousands of genes and examine hundreds of variants of those genes. This will allow scientists to more accurately model the complexities of a human disease that could lead to the development of next generation therapeutics or gene therapies for many serious diseases. “
To ensure the success of any type of editing, Eclipse uses machine learning to apply lessons learned from hundreds of thousands of genome edits to hundreds of cell types. With this machine learning in combination with automation, the new platform can reduce costs and increase the scalability of technical cell production. The Eclipse platform has a modular structure and enables upgrades or add-ons to be provided quickly. It is designed to use a cell type independent process and to be of immediate benefit to researchers working with induced pluripotent stem cells (iPS) and immortalized cell lines.
“We are living in a new era of innovation in life sciences – an era that contributed to DNA sequencing and is able to read from biology and now write in and develop biology. We built our Eclipse platform based on the convergence of science and technology to make genome editing more precise, scalable and accessible, ”said Paul Dabrowski, CEO and co-founder of Synthego. “We are excited to expand our influence on the advancement of innovation in the life sciences with the introduction of this unique CRISPR-based platform.”
Welcome to Judah , We`re dedicated to providing you the very best of service and products. We hop you enjoy our service and our products as much as we enjoy offering them. Donations
©Copyright 2021 by JUDAH